Stockscreener 앱 받기
27.16
5.15%
1.33
시간 외 거래:
28.50
1.34
+4.93%
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Ideaya and Hengrui report promising data for DLL3-targeted cancer drug - Investing.com
80% Cancer Response Rate: IDEAYA's First-in-Class Drug IDE849 Shows Promise in Hard-to-Treat Lung Cancer - Stock Titan
The week in pharma: action, reaction and insight – week to September 5 - The Pharma Letter
IDEAYA Biosciences Inc. Reversal Rally May Surprise BearsQuarterly Market Review & Free Real-Time Volume Trigger Notifications - beatles.ru
Ideaya Biosciences stock hits 52-week low at $21.02 - MSN
Real time alert setup for IDEAYA Biosciences Inc. performancePortfolio Risk Summary & Weekly Breakout Watchlists - Newser
Trend analysis for IDEAYA Biosciences Inc. this week2025 Technical Patterns & Fast Entry Momentum Alerts - Newser
How to forecast IDEAYA Biosciences Inc. trends using time seriesWeekly Risk Summary & AI Powered Market Trend Analysis - Newser
Can you recover from losses in IDEAYA Biosciences Inc.2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
Using Python tools to backtest IDEAYA Biosciences Inc. strategiesEarnings Trend Report & Scalable Portfolio Growth Methods - Newser
Quantitative breakdown of IDEAYA Biosciences Inc. recent moveJuly 2025 Institutional & Verified Short-Term Plans - Newser
Real time breakdown of IDEAYA Biosciences Inc. stock performanceQuarterly Investment Review & AI Forecasted Stock Moves - Newser
Best data tools to analyze IDEAYA Biosciences Inc. stockWeekly Trend Report & Risk Adjusted Swing Trade Ideas - Newser
Measuring IDEAYA Biosciences Inc.’s beta against major indicesQuarterly Trade Review & Risk Controlled Daily Plans - Newser
IDEAYA Biosciences Inc. stock daily chart insightsTrade Entry Summary & Proven Capital Preservation Methods - Newser
Is IDEAYA Biosciences Inc. stock risky to hold nowJuly 2025 Chart Watch & Free Verified High Yield Trade Plans - خودرو بانک
Comparing IDEAYA Biosciences Inc. in custom built stock radarsDip Buying & Verified Momentum Stock Watchlist - Newser
IDEAYA enrolls first lung cancer patient in targeted therapy trial By Investing.com - Investing.com Nigeria
Will IDEAYA Biosciences Inc. continue its uptrendJuly 2025 Retail & AI Enhanced Trade Execution Alerts - Newser
Can IDEAYA Biosciences Inc. be recession proofPortfolio Value Summary & Smart Money Movement Tracker - خودرو بانک
Is IDEAYA Biosciences Inc.’s ROIC above industry averageJuly 2025 Recap & AI Based Buy and Sell Signals - خودرو بانک
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Ideaya Biosciences stock initiated with Market Outperform rating by Citizens JMP - Investing.com Canada
What machine learning models say about IDEAYA Biosciences Inc.Market Performance Summary & Daily Momentum Trading Reports - Newser
IDEAYA Biosciences Rings the Opening Bell - Nasdaq
Ideaya submits IND for PRMT5 inhibitor - BioWorld MedTech
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - biospace.com
IDEAYA Biosciences: Barclays initiates coverage at Overweight, PT $40. - AInvest
IDEAYA enrolls first lung cancer patient in targeted therapy trial - Investing.com
IDEAYA Biosciences Expands Phase 1/2 Trial for IDE397 and Trodelvy Combination in MTAP-Deletion Non-Small Cell Lung Cancer. - AInvest
First Patient Dosed: Novel MAT2A Inhibitor + Trodelvy Combo Targets 20% of Lung Cancer Patients - Stock Titan
Barclays Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
How high can IDEAYA Biosciences Inc. stock goJuly 2025 Summary & Fast Momentum Entry Tips - Newser
Regression analysis insights on IDEAYA Biosciences Inc. performanceJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
Is IDEAYA Biosciences Inc. trending in predictive chart modelsAnalyst Upgrade & Weekly High Return Forecasts - Newser
IDEAYA Biosciences: A High-Conviction Biotech Play with Precision Oncology Catalysts - AInvest
Transcript : IDEAYA Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 09 - MarketScreener
Real time scanner hits for IDEAYA Biosciences Inc. explainedIndex Update & Technical Pattern Based Buy Signals - Newser
Is IDEAYA Biosciences Inc. gaining market shareWeekly Trend Summary & Stepwise Swing Trade Plans - خودرو بانک
How hedge fund analytics apply to IDEAYA Biosciences Inc. stockJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - Newser
Ideaya Biosciences stock price target raised to $74 by JPMorgan - Investing.com Canada
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $43 to $74 - 富途牛牛
IDEAYA Biosciences submits IND for new cancer drug IDE892 - Investing.com
IDEAYA Biosciences submits IND for new cancer drug IDE892 By Investing.com - Investing.com Australia
What high frequency data says about IDEAYA Biosciences Inc.Portfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Analyzing IDEAYA Biosciences Inc. with risk reward ratio chartsJuly 2025 Movers & AI Based Buy and Sell Signals - Newser
Risk adjusted return profile for IDEAYA Biosciences Inc. analyzedMarket Trend Report & Growth-Oriented Investment Plans - Newser
Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage - Stock Titan
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors - The Malaysian Reserve
How to escape a deep drawdown in IDEAYA Biosciences Inc.July 2025 Closing Moves & Weekly High Return Forecasts - Newser
Is IDEAYA Biosciences Inc. a cyclical or defensive stock2025 Valuation Update & Safe Entry Zone Tips - خودرو بانک
Backtesting results for IDEAYA Biosciences Inc. trading strategiesTrade Signal Summary & High Win Rate Trade Tips - Newser
1.40%
자본화:
|
볼륨(24시간):